Jonathan Lewis, MD, PhD

Media Releases

Where Precision Meets Impact: Pioneering Immunotherapies that Revolutionize Cancer Treatment

Dr. Jonathan Lewis has joined Syncromune as the Chief Strategy Officer, bringing his wealth of experience in cancer research and immunotherapies to lead the development of an innovative in situ platform therapy for metastatic solid tumor cancers. Syncromune, a clinical-stage biopharmaceutical company, aims to revolutionize cancer treatment with high response rates and potentially improved survival outcomes.

With a distinguished career in global translational and clinical research, Dr. Lewis has held key leadership positions at renowned biopharmaceutical companies. As the former Executive Chairman, CEO, and Chief Medical Officer of Ziopharm Oncology, he spearheaded the development of groundbreaking immunotherapies for metastatic cancers. Prior to that, he served as Chairman and Chief Medical Officer of Antigenics, Inc, focusing on personalized therapeutic vaccines for various diseases.

Dr. Lewis is a highly respected figure in the medical and scientific community, serving as Chairman of three boards and Director of two others. His educational background includes an M.D. from Witwatersrand University and a Ph.D. from Yale University, with additional training at esteemed institutions such as The Royal College of Surgeons in Edinburgh, Cambridge University, and Memorial Sloan-Kettering Cancer Center.

At Memorial Sloan-Kettering Cancer Center in New York, Dr. Lewis made significant contributions as an attending surgeon in the Department of Surgery and as an attending physician in the Clinical Immunology Service, Division of Hematologic Oncology. He also held a professorship at Weill Medical College of Cornell University, and currently serves as an Adjunct Professor at Lankenau Institute for Medical Research.

Recognized for his exceptional leadership and fundraising abilities, Dr. Lewis has raised over 1 billion US dollars in equity, nonprofit, and government funding. His achievements have been acknowledged with prestigious honors and awards in medicine and science, including the ASCO Young Investigator Award, the Kristen Carr Fellowship, the Yale University Ohse Fellowship, the Royal College of Surgeons Trubshaw Medal, the University of Cambridge Churchill Fellowship, the inaugural Kristen Ann Carr Fellowship, and the Sarcoma Foundation of America Hope and Vision Award. His extensive research has led to over 200 scientific publications and contributions to numerous textbooks in the field of cancer biology and treatment.

Syncromune is thrilled to welcome Dr. Jonathan Lewis to its team as Chief Strategy Officer, confident that his expertise and vision will drive the company towards developing innovative cancer therapies that have the potential to transform patient outcomes.

Recommended Articles

• Can Turmeric Help Fight Cancer?

  What is cancer?Cancer is the term given to a group of diseases where cells uncontrollably grow. All types of cancer usually begin in cells and can develop anywhere in the body. It begins when there are changes in a cell or a group of cells.  The human body is composed of millions and millions of...

• After Ovarian Cancer Diagnosis: What to Expect

  No two people are going to experience their diagnosis of ovarian cancer in the same way. Although some emotions, such as shock and grief, are common feelings among those who are newly diagnosed with cancer, not everyone will feel their emotions in the same degree or in the same order. All cancer is...

• Blogging Her Way Through Lymphoma - A 22 Year Old’s Way to Cope

  In May of 2016, Katie DeMasi graduated from the University of Delaware with a Bachelor of Science Degree in Nursing. The young woman already had a job lined up as a registered nurse at NYU Langone Medical Center in New York City. She had picked out her scrubs and spent a few of her summer days...

• What Causes Lung Cancer?

  Lung cancer is the unsuppressed growth of cells in the tissues of the lungs. Such a condition leads to a tumor (malignant) which may spread (by metastasis) to different organs of the body if not treated in time. Cancer of the lung at the primary stage is also known as carcinoma. The two types of...

• New Advancement to Reduce Rate of Breast Cancer Spreading

  One of the most difficult aspects of treating cancer is fighting against the speed at which the cancer spreads throughout the body. As cells grow and multiply, they begin to affect larger systems in the body, and can metastasize to different systems entirely. Once a cancer has spread from the...

• Is it Lung Cancer or COPD?

  Chronic Obstructive Pulmonary Disease (COPD) and lung cancer are two ends of the same spectrum. Though vastly different in core characteristics, they share many symptoms such as painful wheezing, a persistent cough, and the production of copious mucus. Both these diseases have similar causes and...